<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Second-line and subsequent therapies for immune thrombocytopenia (ITP) in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Second-line and subsequent therapies for immune thrombocytopenia (ITP) in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Second-line and subsequent therapies for immune thrombocytopenia (ITP) in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Donald M Arnold, MD, MSc</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Adam Cuker, MD, MS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark Crowther, MD, MSc</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 11, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Therapy for immune thrombocytopenia (ITP) differs for different patients: some do not require any treatment; others have a spontaneous remission or respond to first-line therapy with glucocorticoids; and others continue to have severe thrombocytopenia necessitating additional therapy.</p><p>Here we discuss our approach to management of ITP for adults who require additional therapy beyond glucocorticoids (second-line and subsequent therapies). The clinical manifestations, diagnosis, and initial treatment of adults and children presenting with ITP are discussed in detail separately.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adults</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Diagnosis</strong> – (See  <a class="medical medical_review" href="/z/d/html/6676.html" rel="external">"Immune thrombocytopenia (ITP) in adults: Clinical manifestations and diagnosis"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial treatment</strong> – (See  <a class="medical medical_review" href="/z/d/html/6677.html" rel="external">"Initial treatment of immune thrombocytopenia (ITP) in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Diagnosis</strong> – (See  <a class="medical medical_review" href="/z/d/html/5930.html" rel="external">"Immune thrombocytopenia (ITP) in children: Clinical features and diagnosis"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial treatment</strong> – (See  <a class="medical medical_review" href="/z/d/html/5917.html" rel="external">"Immune thrombocytopenia (ITP) in children: Initial management"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chronic disease</strong> – (See  <a class="medical medical_review" href="/z/d/html/89225.html" rel="external">"Immune thrombocytopenia (ITP) in children: Management of chronic disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnancy</strong> – (See  <a class="medical medical_review" href="/z/d/html/6681.html" rel="external">"Thrombocytopenia in pregnancy", section on 'Immune thrombocytopenia (ITP)'</a>.)</p><p></p><p class="headingAnchor" id="H7052461"><span class="h1">INITIAL CONSIDERATIONS</span></p><p class="headingAnchor" id="H1627961276"><span class="h2">Treatment of bleeding</span><span class="headingEndMark"> — </span>Treatment of patients with acute, severe bleeding and patients who require a higher platelet count for surgery or obstetric indications is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6677.html" rel="external">"Initial treatment of immune thrombocytopenia (ITP) in adults", section on 'Critical bleeding'</a> and  <a class="medical medical_review" href="/z/d/html/6677.html" rel="external">"Initial treatment of immune thrombocytopenia (ITP) in adults", section on 'Surgery or delivery'</a>.)</p><p class="headingAnchor" id="H7052468"><span class="h2">Indications for second-line therapy</span><span class="headingEndMark"> — </span>The goal of ITP therapy is to provide a safe platelet count to prevent clinically important bleeding, not to normalize the platelet count [<a href="#rid1">1</a>]. Second-line therapy is used when first-line therapy (eg, glucocorticoids) does not raise the platelet count to a safe level or if tapering first-line therapy results in a decrease of the platelet count below a safe level  (<a class="graphic graphic_algorithm graphicRef130855" href="/z/d/graphic/130855.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/z/d/html/6677.html" rel="external">"Initial treatment of immune thrombocytopenia (ITP) in adults", section on 'Whom to treat (indications for therapy)'</a>.)</p><p>We often initiate second-line therapy at a slightly lower platelet count than used for initial therapy (ie, &lt;20,000/microL rather than 30,000/microL that is used for initial therapy), especially if the platelet count &lt;20,000/microL is persistent, recurrent, or associated with bleeding symptoms (mucosal purpura or more serious bleeding). A 2019 guideline on ITP from the American Society of Hematology (ASH) considers second-line therapy to be appropriate for these individuals after ≥3 months from diagnosis [<a href="#rid1">1</a>]. However, it is reasonable to start second-line therapy before three months in patients who do not have a response to first-line therapy or who experience a relapse after first-line therapy is tapered. The ASH guideline and an associated consensus report emphasize that therapy should minimize toxicity and optimize the patient's quality of life [<a href="#rid1">1,2</a>]. </p><p>The importance of proceeding to second-line therapy is greater for patients with a higher risk of bleeding due to other comorbidities (eg, hypertension, renal insufficiency), the need for concomitant antiplatelet agents or anticoagulant medications, or athletic activities or careers with high risk for trauma. For patients for whom bleeding is less of a concern, second-line therapy may be deferred even at lower platelet counts. </p><p class="headingAnchor" id="H1101074805"><span class="h2">COVID-19 vaccination</span><span class="headingEndMark"> — </span>We sometimes delay coronavirus disease 2019 (COVID-19) vaccination for individuals who are in the midst of an active ITP flare, due to the possible exacerbation of thrombocytopenia. However individuals with chronic ITP do not need to delay vaccination, and COVID-19 vaccination should not be withheld for individuals who have received (or are receiving) ITP therapy and are not in the midst of a flare. (See  <a class="medical medical_review" href="/z/d/html/6677.html" rel="external">"Initial treatment of immune thrombocytopenia (ITP) in adults", section on 'COVID-19 vaccination'</a>.)</p><p>While COVID-19 vaccination should not be withheld for individuals who have received immunosuppressive therapies, patients and clinicians should be informed about the possible reduced vaccine response (especially after <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>) and the importance of taking other precautions against COVID-19. Additional considerations related to COVID-19 vaccination in individuals receiving immunosuppressive therapies are presented separately. Patients and providers are advised to review the latest recommendations with respect to booster vaccine doses in patients who are receiving immunosuppressive therapy. (See  <a class="medical medical_review" href="/z/d/html/129849.html" rel="external">"COVID-19: Vaccines", section on 'Immunocompromised individuals'</a>.)</p><p class="headingAnchor" id="H2381737207"><span class="h2">Caveats before proceeding to second-line therapy</span><span class="headingEndMark"> — </span>Caveats are summarized in the figure  (<a class="graphic graphic_algorithm graphicRef132516" href="/z/d/graphic/132516.html" rel="external">algorithm 2</a>) and include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic confirmation</strong> – Before proceeding to a second-line agent, it is especially important to confirm the diagnosis of ITP by eliminating other possibilities such as an inherited thrombocytopenia, myelodysplastic syndrome (MDS), or drug-induced thrombocytopenia. In one series of 295 individuals who were initially diagnosed as having ITP, 36 (12 percent) were subsequently reclassified as having a different diagnosis requiring a different management approach [<a href="#rid3">3</a>]. Review of the patient and family history and the complete blood count (CBC) and blood smear for platelet and other cell morphologies are especially important. (See  <a class="medical medical_review" href="/z/d/html/6676.html" rel="external">"Immune thrombocytopenia (ITP) in adults: Clinical manifestations and diagnosis", section on 'Differential diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Possible secondary ITP</strong> – It is important to review possible causes of secondary ITP that might respond to treatment of the underlying condition, such as <em>Helicobacter pylori</em> infection, HIV infection, hepatitis C virus (HCV) infection, or chronic lymphocytic leukemia (CLL) [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/6676.html" rel="external">"Immune thrombocytopenia (ITP) in adults: Clinical manifestations and diagnosis", section on 'Inciting events'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preparation for immunosuppression</strong> – Several second-line and third-line therapies are immunosuppressive, including splenectomy, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, and other immunosuppressive agents. Even if these are not used right away, they may be used in the future. It is prudent to ensure that all regular vaccinations (including coronavirus disease 2019 [COVID-19] vaccination) are updated, and it may be reasonable to provide pre-splenectomy vaccinations in case splenectomy or rituximab is used. Individuals who may receive rituximab should also be screened for active or latent hepatitis B virus (HBV) infection and treated appropriately. (See <a class="local">'Immunizations'</a> below and  <a class="medical medical_review" href="/z/d/html/117640.html" rel="external">"Elective (diagnostic or therapeutic) splenectomy", section on 'Vaccinations'</a> and  <a class="medical medical_review" href="/z/d/html/3649.html" rel="external">"Hepatitis B virus reactivation associated with immunosuppressive therapy"</a>.)</p><p></p><p class="headingAnchor" id="H1350916622"><span class="h2">Immunizations</span><span class="headingEndMark"> — </span>Appropriate immunizations for encapsulated organisms should be administered prior to performing splenectomy. These immunizations should ideally also be administered prior to <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, since anti-CD20 therapy can blunt the immune response to vaccination. While it is optimal to allow sufficient time for a vaccine response, initiation of therapy for ITP should not be delayed while awaiting immune response if therapy is deemed to be required more urgently. Details are presented separately. (See  <a class="medical medical_review" href="/z/d/html/117640.html" rel="external">"Elective (diagnostic or therapeutic) splenectomy", section on 'Vaccinations'</a> and  <a class="medical medical_review" href="/z/d/html/1412.html" rel="external">"Prevention of infection in patients with impaired splenic function", section on 'Vaccinations'</a>.)</p><p class="headingAnchor" id="H7052482"><span class="h1">CHOICE OF SECOND-LINE THERAPY</span></p><p class="headingAnchor" id="H3936618508"><span class="h2">Splenectomy, rituximab, or a TPO-RA</span><span class="headingEndMark"> — </span>Splenectomy, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, or a thrombopoietin receptor agonist (TPO-RA) are the three principal choices of second-line treatment; they differ in their mechanism of action [<a href="#rid4">4</a>]. All three are effective in raising the platelet count in the majority of individuals, but they differ dramatically in their application, duration, costs, burdens, and adverse effects profiles. </p><p>Splenectomy is a one-time permanent surgical procedure that is the most likely of the three principal therapies to result in a durable response; <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> typically requires four weekly intravenous administrations and may need to be re-administered; TPO-RAs typically require administration for an extended period of time, although responses are sometimes maintained even after stopping treatment. Splenectomy carries operative and other risks. Splenectomy and rituximab both cause immunosuppression (indefinite for splenectomy, potentially prolonged for rituximab).</p><p>As a result, the choice of therapy is highly dependent upon patient values and preferences. We discuss all three options with patients and assist them in balancing the risks and benefits of each approach, which are summarized in the table  (<a class="graphic graphic_table graphicRef95678" href="/z/d/graphic/95678.html" rel="external">table 1</a>). A decision tree that incorporates patient values and preferences is illustrated in the algorithm  (<a class="graphic graphic_algorithm graphicRef132516" href="/z/d/graphic/132516.html" rel="external">algorithm 2</a>). </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Splenectomy</strong> – Splenectomy may be a good choice for an individual who wishes to have a single potentially curative surgical procedure and who is willing to accept the increased risks of infection and venous thromboembolism. Compared with open splenectomy, laparoscopic splenectomy has a lower surgical mortality and complication rate, shorter hospitalization, and faster recovery. Pre-splenectomy vaccinations are critical. (See <a class="local">'Decision to pursue splenectomy'</a> below and <a class="local">'Caveats before proceeding to second-line therapy'</a> above.)</p><p></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rituximab</strong> – <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> may be a good choice for an individual who wishes to avoid surgery and prefers not to take a medication long term. However, its effect is often short-lived, necessitating redosing or use of another second line agent. (See <a class="local">'Rituximab evidence for efficacy'</a> below.)</p><p></p><p class="bulletIndent1">We are trying to avoid <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> during the coronavirus disease 2019 (COVID-19) pandemic because it can blunt vaccine responses. (See <a class="local">'Rituximab'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>TPO-RA</strong> – A TPO-RA may be a good choice for an individual who is especially concerned about immunosuppression following splenectomy or <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> and who is less concerned about the need to take a medication for an extended period of time, including the associated costs and burdens. (See <a class="local">'Decision to use a TPO-RA'</a> below.)</p><p></p><p class="bulletIndent1">Temporary use of a TPO-RA may be appropriate during the COVID-19 pandemic as a means of avoiding immunosuppressive therapy.</p><p></p><p>If splenectomy is chosen, it is generally preferable to wait at least one year from the time of diagnosis in case a spontaneous remission occurs. During this time, a TPO-RA may be used temporarily while surgery is being scheduled and preoperative vaccines administered (see <a class="local">'Immunizations'</a> above). A TPO-RA may also be useful for those who require a temporary increase in platelet count in preparation for splenectomy and do not have an adequate platelet count response to glucocorticoids [<a href="#rid5">5</a>].</p><p>The 2019 American Society of Hematology (ASH) guideline on ITP makes weak recommendations for a TPO-RA over <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> and for rituximab over splenectomy, but the guideline emphasizes the potential usefulness of all three treatments and the importance of patient characteristics (age, ITP history, comorbidities), values, and preferences in the final decision [<a href="#rid1">1</a>].</p><p>Some experts prefer other therapies, such as <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (MMF) over <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, despite having less evidence from randomized trials. (See <a class="local">'Other therapies'</a> below.)</p><p class="headingAnchor" id="H2164424834"><span class="h2">Relative efficacy and toxicity</span><span class="headingEndMark"> — </span>Overall efficacy of splenectomy, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, and TPO-RAs is discussed in the sections below. (See <a class="local">'Decision to pursue splenectomy'</a> below and <a class="local">'Rituximab evidence for efficacy'</a> below and <a class="local">'Decision to use a TPO-RA'</a> below.)</p><p>These therapies (or any pairwise combinations) have not been directly compared in randomized trials [<a href="#rid6">6</a>]. However, the reported initial response rates with splenectomy are higher than with <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> (60 to 80 percent versus 55 to 65 percent, respectively) and responses with splenectomy are more durable (often lasting for many years or even indefinitely for splenectomy, versus one to two years for rituximab) [<a href="#rid7">7-13</a>]. There are also significant differences in short-term and long-term risks of splenectomy versus rituximab  (<a class="graphic graphic_table graphicRef95678" href="/z/d/graphic/95678.html" rel="external">table 1</a>) [<a href="#rid14">14,15</a>].</p><p>In an unpublished retrospective cohort study comparing TPO-RAs with <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> in 429 individuals with chronic ITP, survival rates were similar, but toxicities were less with TPO-RAs [<a href="#rid16">16</a>]. Rituximab-related morbidities included infection (pneumonia, sepsis) and thrombotic complications (venous thromboembolism, myocardial infarction). There are significant differences in short-term and long-term risks and burdens of rituximab versus TPO-RAs; namely, rituximab causes immunosuppression and may work only transiently, and TPO-RAs are highly effective but require extended administration in many cases.</p><p class="headingAnchor" id="H4096883880"><span class="h2">Other options</span><span class="headingEndMark"> — </span>Other therapies may be appropriate if splenectomy, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, and/or a TPO-RA are ineffective or cannot be used. (See <a class="local">'Other therapies'</a> below.)</p><p class="headingAnchor" id="H16547568"><span class="h1">SPLENECTOMY</span><span class="headingEndMark"> — </span>Splenectomy removes the major site of phagocytosis of antibody-coated platelets, as well as lymphocytes that reside in the spleen that might be responsible for producing antiplatelet antibodies. As such, it effectively targets multiple pathophysiologic mechanisms of ITP and has the greatest potential to modify the course of the disease [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/z/d/html/7134.html" rel="external">"Splenomegaly and other splenic disorders in adults", section on 'Properties of the normal spleen'</a>.)</p><p class="headingAnchor" id="H10200020"><span class="h2">Decision to pursue splenectomy</span><span class="headingEndMark"> — </span>As noted above and summarized in the algorithm  (<a class="graphic graphic_algorithm graphicRef132516" href="/z/d/graphic/132516.html" rel="external">algorithm 2</a>), splenectomy may be a good choice for an individual who wishes to have a single potentially curative surgical procedure and who is willing to accept the small increased risks of infection and venous thromboembolism. Preference for splenectomy may also correlate with the local surgical expertise. (See <a class="local">'Choice of second-line therapy'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy and adverse events</strong> – Of all the ITP therapies, splenectomy has the greatest chance of altering the disease course and resulting in a sustained remission [<a href="#rid7">7,18</a>]. However, splenectomy has the greatest associated risk, including operative risks and postoperative risks of immunosuppression and increased rate of thromboembolic complications. (See <a class="local">'Splenectomy risks'</a> below.)</p><p></p><p class="bulletIndent1">The high rate of sustained remission and toxicity profile of splenectomy were illustrated in a systematic review of splenectomy for ITP that included data for 47 case series (2623 adults) and over 50 years of observation, published in 2004 [<a href="#rid7">7</a>]. Platelet counts normalized in 66 percent of individuals and increased to &gt;50,000/microL in an additional 22 percent, for a total response rate of 88 percent. Responses persisted throughout the duration of monitoring (up to over 12 years)  (<a class="graphic graphic_figure graphicRef59587" href="/z/d/graphic/59587.html" rel="external">figure 1</a>). The complication rates were 13 percent with open splenectomy and 10 percent with laparoscopic splenectomy. Mortality was 1 percent with open splenectomy and 0.2 percent with laparoscopy. (See <a class="local">'Splenectomy risks'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Predicting response</strong> – The only clinical parameter that predicts a favorable response to splenectomy is patient age; younger patients have a higher response rate, although a specific age cutoff below which splenectomy was most effective could not be determined [<a href="#rid7">7,19-22</a>]. One study reported that the duration of response following splenectomy and the likelihood of response may be reduced in patients older than 65 years [<a href="#rid20">20</a>]. Another study found a correlation between response to intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG) and response to splenectomy [<a href="#rid23">23</a>]; however, this may represent better patient selection. </p><p></p><p class="bulletIndent1">In some centers, a radiolabeled tracer scan (indium, chromium) is used to determine the degree of splenic sequestration of platelets, which is thought to correlate with the likelihood of a good response to splenectomy. A 2020 meta-analysis of studies using this approach in 2966 individuals with ITP demonstrated a correlation between a splenic sequestration pattern and a good response to splenectomy, relative to other patterns (hepatic, mixed, or unknown) [<a href="#rid24">24</a>]. Response rates were 87 percent with a splenic pattern versus 47 percent with a mixed pattern and 26 percent with a hepatic pattern. This type of scanning to predict response to splenectomy is not routinely used in the United States. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing</strong> – If splenectomy is pursued, it is generally prudent to wait at least 12 months from diagnosis since spontaneous remissions are possible. (See <a class="local">'Timing of splenectomy'</a> below.)</p><p></p><p class="bulletIndent1">Platelet counts typically rise within the first two weeks postoperatively  (<a class="graphic graphic_table graphicRef87698" href="/z/d/graphic/87698.html" rel="external">table 2</a>). Platelet count increases within one to two days can also occur, and delayed responses (up to eight weeks or longer) have been observed [<a href="#rid25">25</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Accessory spleen</strong> – For patients who have persistent thrombocytopenia following splenectomy, we generally proceed to another second-line therapy or, if all second-line options have been exhausted, to a third-line therapy. We do not pursue a diagnosis of an accessory spleen or perform accessory splenectomy in patients with persistent thrombocytopenia following splenectomy. However, this approach has been used in rare patients who have a late recurrence of ITP after splenectomy. Absence of Howell-Jolly bodies  (<a class="graphic graphic_picture graphicRef60588" href="/z/d/graphic/60588.html" rel="external">picture 1</a>) on the peripheral blood smear may be a clue to persistent splenic tissue or splenic tissue regrowth. (See  <a class="medical medical_review" href="/z/d/html/4435.html" rel="external">"Evaluation of the peripheral blood smear", section on 'Howell-Jolly bodies'</a>.)</p><p></p><p class="headingAnchor" id="H663275"><span class="h2">Timing of splenectomy</span><span class="headingEndMark"> — </span>Decisions about when to perform splenectomy can be challenging because of the possibility of a late spontaneous remission. Many clinicians prefer to delay splenectomy with the hope that a spontaneous remission will occur and render the procedure unnecessary [<a href="#rid17">17</a>]. However, data to predict which patients will undergo spontaneous remission (and thus might avoid splenectomy) are lacking, and there is not a clear cutoff time after which spontaneous remissions become less likely. </p><p>We individualize the timing of splenectomy based on the patient's clinical features, response to initial therapy, and other considerations (eg, patient preference). In practice, we often wait at least 12 months from diagnosis of ITP to splenectomy, to allow for late spontaneous remissions; this practice is consistent with the 2019 ASH ITP guidelines [<a href="#rid1">1</a>]. Some patients with persistently severe and symptomatic thrombocytopenia despite medical therapy may require splenectomy sooner.</p><p class="headingAnchor" id="H663295"><span class="h2">Pre-splenectomy considerations</span><span class="headingEndMark"> — </span>Additional issues for patients considering splenectomy include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunizations</strong> – Patients considering splenectomy should receive immunizations for encapsulated organisms at least two weeks prior to the procedure if possible and if these were not done already. These individuals are often prescribed antibiotics to take in the event of fever. Details of the impact of immunosuppression on response to vaccination, specific vaccination schedules, and other infection prevention are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/117640.html" rel="external">"Elective (diagnostic or therapeutic) splenectomy", section on 'Preoperative considerations'</a> and  <a class="medical medical_review" href="/z/d/html/1412.html" rel="external">"Prevention of infection in patients with impaired splenic function", section on 'Vaccinations'</a> and  <a class="medical medical_review" href="/z/d/html/1412.html" rel="external">"Prevention of infection in patients with impaired splenic function", section on 'Emergency antibiotic supply'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Optimizing the preoperative platelet count</strong> – If the platelet count needs to be increased for splenectomy, the patient can be treated with intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG), glucocorticoids, or a thrombopoietin receptor agonist (TPO-RA). We prefer to perform splenectomy with a platelet count of ≥50,000/microL; however, many patients with ITP have undergone open or laparoscopic splenectomy safely in the setting of more severe thrombocytopenia, with platelets available for transfusion if urgently needed because of intraoperative bleeding [<a href="#rid26">26</a>]. (See  <a class="medical medical_review" href="/z/d/html/6677.html" rel="external">"Initial treatment of immune thrombocytopenia (ITP) in adults", section on 'Surgery or delivery'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Operative technique</strong> – Laparoscopic splenectomy has become the standard operative technique [<a href="#rid17">17</a>]. This is based on the lower rates of morbidity and mortality reported in a systematic review that included over 3000 splenectomies in patients with ITP (mortality rate of 1 percent with open and 0.2 percent with laparoscopic procedures) [<a href="#rid7">7</a>]. Practices and surgical outcomes may differ at different institutions. (See  <a class="medical medical_review" href="/z/d/html/117640.html" rel="external">"Elective (diagnostic or therapeutic) splenectomy", section on 'Surgical approach'</a>.)</p><p></p><p>Other general preoperative considerations (eg, cardiac risk assessment, preoperative thyroid function testing) are presented separately. (See  <a class="medical medical_review" href="/z/d/html/6616.html" rel="external">"Evaluation of cardiac risk prior to noncardiac surgery"</a> and  <a class="medical medical_review" href="/z/d/html/4816.html" rel="external">"Preoperative medical evaluation of the healthy adult patient"</a> and  <a class="medical medical_review" href="/z/d/html/7858.html" rel="external">"Nonthyroid surgery in the patient with thyroid disease", section on 'Is preoperative measurement of TSH necessary?'</a>.)</p><p class="headingAnchor" id="H663325"><span class="h2">Splenectomy risks</span><span class="headingEndMark"> — </span>The risks of splenectomy include those of the surgical procedure as well as long-term risks of increased susceptibility to infection and possibly vascular events [<a href="#rid27">27</a>]. In a systematic review that included 47 case series of splenectomy for ITP, complications occurred in 88 of 921 patients who underwent laparoscopic splenectomy (10 percent) and 318 of 2465 who underwent open splenectomy (13 percent) [<a href="#rid7">7</a>]. These and other potential complications are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/117640.html" rel="external">"Elective (diagnostic or therapeutic) splenectomy", section on 'Postoperative risks'</a>.)</p><p>Risks of splenectomy compared with other second-line therapies are summarized in the table  (<a class="graphic graphic_table graphicRef95678" href="/z/d/graphic/95678.html" rel="external">table 1</a>). </p><p class="headingAnchor" id="H16539965"><span class="h1">RITUXIMAB</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> is a chimeric monoclonal antibody (mAb) directed against the B cell surface protein CD20. Several biosimilar products have been approved, and we use these interchangeably with rituximab. These antibodies are thought to eliminate B cells via apoptosis, antibody-dependent cytotoxicity, and complement-mediated lysis [<a href="#rid28">28</a>]. Plasma cells responsible for long-term antibody production do not express CD20; this may explain the shorter durations of response relative to response durations seen with splenectomy.</p><p><a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> is immunosuppressive, and during the coronavirus disease 2019 (COVID-19) pandemic we have tried to avoid using rituximab because it blunts the immune response to vaccinations, including COVID-19 vaccines, probably for at least 6 months. </p><p>COVID-19 vaccination should not be withheld for individuals who have recently received <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, but antibody responses may need to be assessed and/or repeat vaccination considered. </p><p>Patients and clinicians should be informed about the possible reduced vaccine response and the importance of taking other precautions against COVID-19. Additional considerations related to COVID-19 vaccination in individuals receiving <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> and general precautions are presented separately. Patients and providers are advised to review the latest recommendations with respect to booster vaccine doses in patients who are receiving immunosuppressive therapy. (See  <a class="medical medical_review" href="/z/d/html/129849.html" rel="external">"COVID-19: Vaccines", section on 'Immunocompromised individuals'</a> and  <a class="medical medical_review" href="/z/d/html/126981.html" rel="external">"COVID-19: Epidemiology, virology, and prevention", section on 'Prevention'</a>.)</p><p class="headingAnchor" id="H7052670"><span class="h2">Rituximab evidence for efficacy</span><span class="headingEndMark"> — </span>As noted above and summarized in the flowchart  (<a class="graphic graphic_algorithm graphicRef132516" href="/z/d/graphic/132516.html" rel="external">algorithm 2</a>), <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> may be a good choice for an individual who wishes to avoid surgery and prefers not to take a medication for an extended period of time; however, the short duration of its effect may mandate retreatment or an additional second-line therapy. (See <a class="local">'Choice of second-line therapy'</a> above.)</p><p>The overall efficacy of single-agent <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> therapy is in the range of 40 to 60 percent based on data from several large reviews and meta-analyses. The median duration of effect is approximately one year, and some individuals may require retreatment. </p><p class="bulletIndent1"><span class="glyph">●</span>A 2015 meta-analysis of randomized trials that compared <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> plus standard care versus standard care alone (five trials; 463 patients) found a modest benefit of rituximab in improving platelet counts [<a href="#rid29">29</a>]. A sustained complete platelet count response (platelet count &gt;100,000/microL) at 6 months occurred in 47 percent of patients who received rituximab and 33 percent of controls (relative risk [RR] 1.42, 95% CI 1.13-1.77). A partial response (platelet count above 30,000 to 50,000/microL) occurred in 58 percent of patients who received rituximab compared with 47 percent of controls.</p><p></p><p class="bulletIndent1">In the trial with the longest follow-up (median, 1.5 years), however, responses with <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> more closely approached placebo (complete responses in 16 percent of individuals treated with rituximab versus 7 percent treated with placebo; RR 2.21, 95% CI 0.72-6.75) [<a href="#rid11">11</a>]. Avoidance of splenectomy (or avoidance of the criteria for splenectomy [platelet count &lt;20,000/microL or need for continued glucocorticoid therapy]) was seen in 81 percent of the rituximab group and 73 percent of the placebo groups). Three late spontaneous remissions occurred, more than a year after randomization, in patients receiving no therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis from 2012 that included randomized trials and observational studies in which non-splenectomized individuals were treated with <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> found an overall response rate of 57 percent and platelet counts &gt;100,000/microL in 41 percent [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 2007 systematic review of observational studies of (313 adults) found complete responses in 44 percent and platelet count &gt;50,000/microL in 63 percent [<a href="#rid9">9</a>]. Approximately one-half of the individuals had undergone splenectomy, and responses were similar in the prior splenectomy and no splenectomy groups. The median time to response was 5.5 weeks from the first dose of <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, and the median response duration was 11 months (interquartile ranges, three to seven weeks and 6 to 18 months, respectively). Toxicities were mild, including grade 1 to 2 infusion reactions and other minor reactions. Ten patients had more serious reactions (eg, infections, allergic reactions, thromboemboli), and there were nine deaths (2.9 percent). Causes of death included infections and bleeding; many of the patients had serious underlying comorbidities.</p><p></p><p>Although the median duration of response to <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> (approximately one year) is shorter than splenectomy, some individuals can have long-lasting responses. This was illustrated in a study that evaluated the duration of response in 72 adults who had an initial response to rituximab that lasted for at least one year and 66 children with a response of any duration [<a href="#rid8">8</a>]. After five years of observation, 21 percent of adults and 26 percent of children had a continued response. It is unclear whether these long-lasting responses are attributable to rituximab or whether these cases were destined to remit spontaneously.</p><p class="headingAnchor" id="H1533140719"><span class="h2">Rituximab planning and dosing</span><span class="headingEndMark"> — </span>Patients should be screened for hepatitis B virus (HBV) infection before starting <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> because of the risk of HBV reactivation. Rituximab is generally avoided in individuals with active or occult HBV infection; if rituximab must be used, prophylactic anti-HBV treatment against hepatitis B should be considered in consultation with an infectious disease specialist or hepatologist. (See  <a class="medical medical_review" href="/z/d/html/3642.html" rel="external">"Hepatitis B virus: Overview of management"</a>.)</p><p>Treatment with <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> can suppress vaccine responses for at least six months after administration. Thus, we provide appropriate immunizations prior to starting rituximab therapy [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/z/d/html/1412.html" rel="external">"Prevention of infection in patients with impaired splenic function", section on 'Vaccinations'</a>.)</p><p>The dose of <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> typically used in patients with ITP is 375 mg/m<sup>2</sup> intravenously once a week for four consecutive weeks. We favor this dosing based on more extensive experience with it, although we understand that lower doses may be sufficient for ITP therapy compared with hematologic malignancies. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>A study that treated 48 patients with <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> at 100 mg/week for four weeks found similar efficacy to higher doses (response in 60 percent, platelet count normalized in 40 percent) [<a href="#rid32">32,33</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A study that treated 108 patients with two fixed doses of <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> (1000 mg on days 1 and 15) showed a response rate of 44 percent [<a href="#rid34">34</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A study that treated 248 patients with either 375 mg/m<sup>2</sup> once a week for four weeks or 1000 mg on days 1 and 15 (choice of regimen based on clinician preference) showed similar efficacy of the two regimens, with initial responses in 152 patients (62 percent and 61 percent) and lasting responses at two years in 96 patients (39 percent and 40 percent) [<a href="#rid35">35</a>]. </p><p></p><p>Responses to <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> can occur within a week but may take up to two months  (<a class="graphic graphic_table graphicRef87698" href="/z/d/graphic/87698.html" rel="external">table 2</a>). Rituximab may be administered in combination with other treatments because its effects on platelet count can be delayed.</p><p class="headingAnchor" id="H663409"><span class="h2">Rituximab toxicities</span><span class="headingEndMark"> — </span>Adverse effects of <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> include infusion reactions and prolonged immunosuppression, which can result in reactivation of HBV infection [<a href="#rid35">35</a>]. Progressive multifocal leukoencephalopathy (PML) has been reported following rituximab for ITP; many of the affected individuals had been pretreated with other immunosuppressive agents in addition to rituximab [<a href="#rid36">36</a>]. Boxed warnings for infusion reactions, hepatitis B reactivation, mucocutaneous reactions, and PML are included in the prescribing information. These toxicities are discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/7501.html" rel="external">"Rituximab: Principles of use and adverse effects in rheumatoid arthritis", section on 'Adverse effects'</a> and  <a class="medical medical_review" href="/z/d/html/3649.html" rel="external">"Hepatitis B virus reactivation associated with immunosuppressive therapy"</a>.)</p><p>As noted above, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> has been reported to interfere with response to immunizations, which is of potential concern in patients who may subsequently undergo splenectomy; we provide immunizations prior to administering rituximab. (See <a class="local">'Immunizations'</a> above.)</p><p>The mechanisms by which <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> may cause immunosuppression are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3939.html" rel="external">"Secondary immunodeficiency induced by biologic therapies", section on 'Rituximab'</a>.)</p><p class="headingAnchor" id="H5"><span class="h1">TPO RECEPTOR AGONISTS</span><span class="headingEndMark"> — </span>Thrombopoietin receptor agonists (TPO-RAs), also called TPO mimetics, include small molecule peptide and non-peptide agents. These act by stimulating the production of megakaryocytes and ultimately platelets in the bone marrow by binding to and activating the TPO receptor. (See  <a class="medical medical_review" href="/z/d/html/6673.html" rel="external">"Biology and physiology of thrombopoietin"</a>.)</p><p class="headingAnchor" id="H7055007"><span class="h2">Decision to use a TPO-RA</span><span class="headingEndMark"> — </span>As noted above and summarized in the flowchart  (<a class="graphic graphic_algorithm graphicRef132516" href="/z/d/graphic/132516.html" rel="external">algorithm 2</a>), a TPO-RA may be a good choice for an individual who wishes to avoid surgery and the immunosuppressive effects of splenectomy or <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> and who is less concerned about the need to take a medication for an extended period of time. (See <a class="local">'Choice of second-line therapy'</a> above.)</p><p>Approximately 80 percent of individuals with ITP will have a significant platelet count increase in response to a TPO-RA [<a href="#rid37">37,38</a>]. Several reports have documented sustained responses in some individuals with ITP after discontinuation of a TPO-RA, with response rates up to 30 to 50 percent, although observation periods have been relatively short (&lt;1 year) [<a href="#rid17">17,39,40</a>]. In most individuals, these agents do not induce remission, and prolonged maintenance therapy is usually required. If treatment is discontinued, platelet counts generally return to baseline levels or even below baseline ("rebound thrombocytopenia").</p><p class="headingAnchor" id="H10199258"><span class="h2">Choice of TPO-RA</span><span class="headingEndMark"> — </span>Available TPO-RAs for ITP include <a class="drug drug_general" data-topicid="9493" href="/z/d/drug information/9493.html" rel="external">romiplostim</a>, <a class="drug drug_general" data-topicid="9051" href="/z/d/drug information/9051.html" rel="external">eltrombopag</a>, and <a class="drug drug_general" data-topicid="117929" href="/z/d/drug information/117929.html" rel="external">avatrombopag</a>. They are all effective, but their relative efficacy in ITP has not been evaluated in randomized trials. The 2019 American Society of Hematology (ASH) guideline does not express a preference for one TPO-RA and suggests a choice between romiplostim or eltrombopag based on patient preferences for route of administration [<a href="#rid1">1</a>]. We individualize the choice based on availability, cost, patient comorbidities, and patient preference. Some individuals have a strong preference for one administration route (oral or subcutaneous) over the other.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9493" href="/z/d/drug information/9493.html" rel="external">Romiplostim</a> (Nplate) is administered as a once-weekly subcutaneous injection. It is a recombinant protein that contains a peptide with four binding sites for the TPO receptor linked to an IgG1-Fc component, termed a "peptibody" [<a href="#rid41">41-43</a>]. (See <a class="local">'TPO-RAs dosing and monitoring'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9051" href="/z/d/drug information/9051.html" rel="external">Eltrombopag</a> (Promacta, Revolade) and <a class="drug drug_general" data-topicid="117929" href="/z/d/drug information/117929.html" rel="external">avatrombopag</a> (Doptelet; approved for ITP in 2018) are given as a once-daily pill. They are non-peptide small molecules that activate the TPO receptor. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9051" href="/z/d/drug information/9051.html" rel="external">Eltrombopag</a> should be dose reduced or avoided in patients with liver disease or increased liver enzymes. Dose reductions are recommended for patients of East Asian descent. Prescribing information includes a Boxed Warning regarding risks of hepatic decompensation in individuals with chronic hepatitis taking <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a> or interferon and risks of hepatotoxicity. It is taken without food or with food low in calcium. (See <a class="local">'TPO-RAs dosing and monitoring'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="117929" href="/z/d/drug information/117929.html" rel="external">Avatrombopag</a> can be taken with food. (See <a class="local">'TPO-RAs dosing and monitoring'</a> below.)</p><p></p><p>Recombinant human TPO has been used in China [<a href="#rid44">44,45</a>]. Recombinant pegylated TPO products such as recombinant PEGylated megakaryocyte growth and development factor (PEG-rHuMGDF) are not used in patients with ITP, following reports of the development of anti-TPO antibodies in response to one of the products that caused severe thrombocytopenia. (See  <a class="medical medical_review" href="/z/d/html/6671.html" rel="external">"Clinical applications of thrombopoietic growth factors", section on 'Recombinant thrombopoietins'</a> and  <a class="medical medical_review" href="/z/d/html/6671.html" rel="external">"Clinical applications of thrombopoietic growth factors", section on 'Antibody formation'</a>.)</p><p class="headingAnchor" id="H1689717267"><span class="h2">TPO-RAs dosing and monitoring</span><span class="headingEndMark"> — </span>TPO-RAs are titrated to keep the platelet count in a safe range (typically, ≥50,000/microL) without causing thrombocytosis. Dosing starts with a low initial dose that is adjusted as needed, with close monitoring of the platelet count until a stable dose is reached.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Romiplostim</strong> – Subcutaneous injection once-weekly. Typical starting dose, 2 to 3 mcg/kg. Most patients in the clinical trials required 3 to 8 mcg/kg (range from 1 to 10 mcg/kg) [<a href="#rid46">46,47</a>]. </p><p></p><p class="bulletIndent2">Vials contain either 250 mcg or 500 mcg of the drug, which would equal approximately 3 mcg/kg or 6 mcg/kg for an 80 kg patient. [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Eltrombopag</strong> – Oral pill once daily. Absorption is reduced by polyvalent cations; <a class="drug drug_general" data-topicid="9051" href="/z/d/drug information/9051.html" rel="external">eltrombopag</a> should be taken without a meal or with a meal low in calcium (≤50 mg) and at least two hours before and four hours after calcium-containing foods, medications such as antacids, and supplements containing polyvalent cations such as calcium, iron, aluminum, magnesium, <a class="drug drug_general" data-topicid="9884" href="/z/d/drug information/9884.html" rel="external">selenium</a>, or zinc. </p><p></p><p class="bulletIndent2">Initial dose, 50 mg daily, or 25 mg once daily in individuals of East-Asian ancestry (Chinese, Japanese, Korean, Taiwanese) and individuals with moderate or severe liver insufficiency [<a href="#rid48">48</a>]. </p><p></p><p class="bulletIndent2"><a class="drug drug_general" data-topicid="9051" href="/z/d/drug information/9051.html" rel="external">Eltrombopag</a> inhibits the transporter, OATP1B1, which is responsible for transporting certain drugs such as <a class="drug drug_general" data-topicid="10282" href="/z/d/drug information/10282.html" rel="external">rosuvastatin</a>. Patients should be monitored closely for toxicities of OATP1B1 substrates and/or they may decrease the dose of these drugs. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Avatrombopag</strong> – Oral pill once daily, taken with food. There are no interactions with dairy products or other medications and there is less risk of hepatotoxicity compared with <a class="drug drug_general" data-topicid="9051" href="/z/d/drug information/9051.html" rel="external">eltrombopag</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Platelet count monitoring</strong> – For all of these agents, platelet counts increase in approximately 7 to 14 days  (<a class="graphic graphic_table graphicRef87698" href="/z/d/graphic/87698.html" rel="external">table 2</a>) [<a href="#rid49">49</a>]. </p><p></p><p class="bulletIndent1">To avoid risks of thrombocytosis, we generally check the platelet count:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Approximately one week after starting therapy</p><p class="bulletIndent2"><span class="glyph">•</span>Approximately one week after dose changes</p><p class="bulletIndent2"><span class="glyph">•</span>Monthly after a stable dose is reached</p><p class="bulletIndent2"><span class="glyph">•</span>If there is a concern about thrombocytopenia (eg, petechiae, mucosal bleeding, intercurrent illness)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other monitoring</strong> – As noted, the following additional laboratory tests are appropriate:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Liver enzymes</strong> – For <a class="drug drug_general" data-topicid="9051" href="/z/d/drug information/9051.html" rel="external">eltrombopag</a>, liver enzymes should be measured prior to drug initiation, every two weeks during dose adjustments, and monthly thereafter.</p><p></p><p class="headingAnchor" id="H3386275386"><span class="h2">TPO-RAs efficacy and adverse events</span><span class="headingEndMark"> — </span>As noted above, TPO-RAs have not been directly compared in individuals with ITP. (See <a class="local">'Choice of TPO-RA'</a> above.)</p><p>The efficacy and toxicities of individual TPO-RAs have been evaluated in various clinical trials such as the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Romiplostim</strong> – The efficacy of <a class="drug drug_general" data-topicid="9493" href="/z/d/drug information/9493.html" rel="external">romiplostim</a> in raising platelet counts is approximately 80 percent, with higher response rates when transient responses are included [<a href="#rid50">50-53</a>]. The following studies illustrate the range of findings:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A pooled analysis of data from 14 trials involving 1059 patients treated with <a class="drug drug_general" data-topicid="9493" href="/z/d/drug information/9493.html" rel="external">romiplostim</a> for up to five and a half years found no difference in the rates of thrombosis, hematologic malignancy/dysplasia, or non-hematologic malignancies over that seen in controls [<a href="#rid54">54</a>]. Bone marrow reticulin was seen in 17 of 921 patients receiving romiplostim and 1 of 65 patients receiving placebo (1.8 versus 1.5 percent); an additional romiplostim-treated patient had increased collagen. Other series have reported rates of adverse events in the range of 13 percent, with thrombotic events in the range of 5 to 7 percent [<a href="#rid46">46,54,55</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An open-label randomized trial from 2010 in 234 patients with ITP found a higher rate of platelet count responses with <a class="drug drug_general" data-topicid="9493" href="/z/d/drug information/9493.html" rel="external">romiplostim</a> (platelet count &gt;50,000/microL: 71 to 92 percent with romiplostim versus 26 to 51 percent with standard care); the proportion undergoing splenectomy was also lower (9 percent with romiplostim versus 36 percent with standard care) [<a href="#rid47">47</a>]. Serious adverse events occurred in 23 percent of romiplostim-treated patients versus 37 percent of controls.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A randomized trial from 2008 in 125 adults with ITP found responses to <a class="drug drug_general" data-topicid="9493" href="/z/d/drug information/9493.html" rel="external">romiplostim</a> in 38 percent of individuals with prior splenectomy and 61 percent without prior splenectomy, versus 0 to 5 percent with placebo [<a href="#rid51">51</a>]. Additional romiplostim-treated patients had transient responses. Response to romiplostim was accompanied by decreased bleeding and an improvement in health-related quality of life as measured by the ITP-Patient Assessment Questionnaire [<a href="#rid56">56</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A series of 292 adults treated with <a class="drug drug_general" data-topicid="9493" href="/z/d/drug information/9493.html" rel="external">romiplostim</a> for up to five years found responses in 90 percent [<a href="#rid46">46</a>]. Responses were inversely correlated with the duration of ITP. Overall, 67 percent of patients were able to avoid use of other ITP medications such as glucocorticoids. Headache was the most common adverse event.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eltrombopag</strong> – The efficacy of <a class="drug drug_general" data-topicid="9051" href="/z/d/drug information/9051.html" rel="external">eltrombopag</a> in raising platelet counts is in the range of approximately 80 percent, with higher response rates when transient responses are included [<a href="#rid57">57-59</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A 2011 trial (RAISE) randomly assigned 197 adults with chronic ITP and platelet count &lt;30,000/microL to <a class="drug drug_general" data-topicid="9051" href="/z/d/drug information/9051.html" rel="external">eltrombopag</a> or placebo and found platelet count responses in 79 percent of eltrombopag-treated patients (versus 28 percent with placebo) [<a href="#rid58">58</a>]. Durable responses occurred in 51 percent of individuals who had previously undergone splenectomy and 66 percent who had not undergone splenectomy (versus 10 percent of controls). Clinically significant bleeding was reduced (33 percent, versus 53 percent with placebo).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The 2013 EXTEND study followed 299 patients treated with <a class="drug drug_general" data-topicid="9051" href="/z/d/drug information/9051.html" rel="external">eltrombopag</a> for up to three years. Responses were seen in 80 and 88 percent of patients with and without splenectomy, and responses were maintained (with continued administration of eltrombopag) for approximately 70 percent of the study duration [<a href="#rid59">59</a>]. A follow-up of EXTEND published in 2017 reported that the median duration of eltrombopag was approximately 2.4 years, and 259 of 302 patients (86 percent) had a platelet count &gt;50,000/microL at least once [<a href="#rid60">60</a>]. Adverse events leading to withdrawal (hepatobiliary changes, cataracts, thrombosis, headache, myelofibrosis) occurred in 41 (14 percent), but rates of hepatobiliary and thromboembolic events did not increase with treatment duration beyond one year.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a 2011 trial that included 197 patients, 17 of 135 (13 percent) discontinued therapy because of adverse events, the most common of which were liver enzyme abnormalities (four patients) and thromboembolic events (two patients) [<a href="#rid58">58</a>]. There were no significant differences in the development of cataracts or malignancies in the <a class="drug drug_general" data-topicid="9051" href="/z/d/drug information/9051.html" rel="external">eltrombopag</a> and placebo groups. Additional studies have not demonstrated other safety concerns [<a href="#rid46">46,59,61,62</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Avatrombopag</strong> – There is less clinical experience with <a class="drug drug_general" data-topicid="117929" href="/z/d/drug information/117929.html" rel="external">avatrombopag</a>, which was approved by the US Food and Drug Administration in 2018.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a 2014 trial in 64 adults with chronic ITP (relapsed or unresponsive to first-line therapy), <a class="drug drug_general" data-topicid="117929" href="/z/d/drug information/117929.html" rel="external">avatrombopag</a> showed a dose-dependent increase in platelet counts (percentage of individuals with a response: 0 responses with placebo, 13 percent with 2.5 mg daily, 53 percent with 5 mg daily, 50 percent with 10 mg daily, and 80 percent with 20 mg daily) [<a href="#rid63">63</a>]. Four individuals had thromboembolic events; most had other risk factors for thromboembolic disease. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a trial from 2018 in 49 adults with chronic ITP and platelet counts &lt;30,000/microL, <a class="drug drug_general" data-topicid="117929" href="/z/d/drug information/117929.html" rel="external">avatrombopag</a> at 20 mg daily resulted in a greater duration of sustained platelet count ≥50,000/microL than placebo (median, 12.4 versus 0 weeks) [<a href="#rid64">64</a>]. There was a very high dropout rate, attributed to lack of a platelet count response, especially in the placebo group, in which only one of 17 completed the full trial. Rates of bleeding and use of rescue medications were similar between groups when adjusted for the difference in length of participation. There were four thromboembolic events; three of these individuals were reported to have risk factors for thromboembolism.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Preclinical studies in animals suggested that excessively high doses of <a class="drug drug_general" data-topicid="117929" href="/z/d/drug information/117929.html" rel="external">avatrombopag</a> might cause carcinoid tumors related to changes in gastrin levels; however, in clinical trials, gastrin levels were normal and no clinical issues were seen [<a href="#rid65">65</a>].</p><p></p><p>Most studies have demonstrated minimal serious adverse events even after administration of these agents for extended periods of time [<a href="#rid46">46</a>]. However, concerns related to the following potential toxicities have been raised:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thrombosis</strong> – All TPO-RAs have been associated with a small increased risk of thrombosis in some populations. However, results from a 2015 meta-analysis suggest that the risk of thrombosis was not increased by <a class="drug drug_general" data-topicid="9493" href="/z/d/drug information/9493.html" rel="external">romiplostim</a> or <a class="drug drug_general" data-topicid="9051" href="/z/d/drug information/9051.html" rel="external">eltrombopag</a> in patients with ITP [<a href="#rid66">66</a>]. Smaller studies with <a class="drug drug_general" data-topicid="117929" href="/z/d/drug information/117929.html" rel="external">avatrombopag</a> suggest that thrombosis is not a risk with short-term treatment, but there are insufficient data to determine the actual risk [<a href="#rid67">67</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone marrow reticulin </strong>– Initial concerns were raised regarding the possibility of increasing bone marrow reticulin formation with <a class="drug drug_general" data-topicid="9493" href="/z/d/drug information/9493.html" rel="external">romiplostim</a> and <a class="drug drug_general" data-topicid="9051" href="/z/d/drug information/9051.html" rel="external">eltrombopag</a>; however, this was not demonstrated in follow-up studies [<a href="#rid54">54</a>]. We do not monitor bone marrow fibrosis in individuals receiving a TPO-RA, as there is no evidence of progression to myelofibrosis and no evidence that serial bone marrow testing leads to improved outcomes. In a romiplostim study using bone marrow surveillance of 131 biopsies, nine (7 percent) demonstrated increases of reticulin and collagen of ≥2 grades on the modified Bauermeister scale after one to three years of treatment [<a href="#rid68">68</a>]. Three of the nine patients had repeat biopsies after stopping the drug that showed resolution of the abnormalities. In an eltrombopag study with 5.5 years of follow-up, moderate reticulin fibrosis of the bone marrow was seen in 2 of 117 patients (1.7 percent) [<a href="#rid69">69</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibodies</strong> – These agents have no sequence homology to thrombopoietin and are not expected to generate inhibitory antibodies.</p><p></p><p>These issues and potential toxicities in patients with other underlying conditions (eg, theoretical risk of hematologic malignancy in patients with myelodysplasia) are discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/6671.html" rel="external">"Clinical applications of thrombopoietic growth factors", section on 'Side effects and risks'</a>.)</p><p class="headingAnchor" id="H14"><span class="h1">OTHER THERAPIES</span><span class="headingEndMark"> — </span>For patients for whom the therapies discussed above are ineffective, not well tolerated, or unavailable, management may be more complex, and a hematologist with experience in managing patients with ITP should be involved in the treatment decisions. </p><p>A number of options are available, as discussed in the following sections. Choices among these therapies vary according to clinician and patient preference, and it may take time to find the best agent for each individual patient. Among the third-line therapies, we generally prefer <a class="drug drug_general" data-topicid="117669" href="/z/d/drug information/117669.html" rel="external">fostamatinib</a> because it is supported by higher-quality evidence than the other options. </p><p class="headingAnchor" id="H591124225"><span class="h2">Fostamatinib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="117669" href="/z/d/drug information/117669.html" rel="external">Fostamatinib</a> (also called fostamatinib disodium or fostamatinib disodium hexahydrate) was approved by the US Food and Drug Administration in mid-2018 for the treatment of thrombocytopenia in adults with chronic ITP who have had an insufficient response to a previous treatment [<a href="#rid70">70</a>]. </p><p><a class="drug drug_general" data-topicid="117669" href="/z/d/drug information/117669.html" rel="external">Fostamatinib</a> is a small molecule prodrug of a tyrosine kinase inhibitor that inhibits Syk (spleen tyrosine kinase). The major metabolite of fostamatinib, R406, is active in Syk inhibition. R406 is thought to increase the platelet count in patients with ITP by reducing phagocytosis and destruction of autoantibody-coated platelets by macrophages, via inhibition of signal transduction through Fc-activating receptors and the B-cell receptor [<a href="#rid71">71,72</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – The initial dose for <a class="drug drug_general" data-topicid="117669" href="/z/d/drug information/117669.html" rel="external">fostamatinib</a> is 100 mg orally twice daily, which can be increased to 150 mg twice daily if the platelet count has not increased to at least 50,000/microL after one month [<a href="#rid73">73</a>]. The complete blood count (CBC) including platelet count should be monitored monthly until stable; liver function tests are monitored monthly; and blood pressure is monitored every two weeks until a stable dose and monthly thereafter. Dose escalations or reductions, drug discontinuation, or the addition of other therapies (eg, antihypertensives, antiemetics) may be required. Like TPO-RAs, this is expected to be a maintenance treatment that must be continuously administered to maintain a safe platelet count.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Side effects</strong> – Side effects of <a class="drug drug_general" data-topicid="117669" href="/z/d/drug information/117669.html" rel="external">fostamatinib</a> include diarrhea, nausea, hypertension, neutropenia, and rash [<a href="#rid74">74,75</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supporting evidence</strong> – Evidence for <a class="drug drug_general" data-topicid="117669" href="/z/d/drug information/117669.html" rel="external">fostamatinib</a> is more limited than for splenectomy, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, or TPO-RAs, but high-quality evidence for efficacy and safety is emerging, making it a reasonable choice among subsequent treatment options. Its role may change (it may become a second-line choice) as more data become available.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In two randomized trials (FIT-1 and FIT-2) from 2018, which together randomly assigned 150 individuals with chronic ITP (median duration, 8.5 years; median platelet count, 16,000/microL) to receive <a class="drug drug_general" data-topicid="117669" href="/z/d/drug information/117669.html" rel="external">fostamatinib</a> or placebo, fostamatinib was associated with a greater rate of stable platelet count &gt;50,000/microL (18 versus 2 percent; p = 0.0003) [<a href="#rid74">74</a>]. Forty-four individuals assigned to placebo underwent crossover to fostamatinib (FIT-3 study), and 10 of these (23 percent) also had a platelet count response. The median time to response was approximately two weeks. Severe and serious bleeding events were reduced with fostamatinib (5 versus 16 percent). The most common adverse events were diarrhea, hypertension, nausea, dizziness, and an increase in alanine aminotransferase (ALT); less common adverse events included neutropenia and rash.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In an open-label extension study, participants in FIT-1 and FIT-2 were followed over a longer duration, stable responses with a median duration of &gt;28 months occurred in 18 percent [<a href="#rid75">75</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the initial 2009 dose-finding study, 16 adults with chronic ITP refractory to at least two other treatments with platelet counts &lt;30,000/microL were treated with <a class="drug drug_general" data-topicid="117669" href="/z/d/drug information/117669.html" rel="external">fostamatinib</a> at increasing doses starting at 75 mg twice daily and increasing up to 150 mg twice daily [<a href="#rid76">76</a>]. Responses, defined as a platelet count increase of at least 20,000/microL, were seen in 12 individuals (75 percent; median peak platelet count 100,000/microL), and responses were sustained in eight (50 percent), some of whom were able to reduce or discontinue other ITP therapies such as intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG) or glucocorticoids. Bleeding was not reported. Adverse events were mostly gastrointestinal (eg, diarrhea with increased urgency, nausea, vomiting, increased hepatic transaminases). Three patients discontinued therapy due to adverse effects.</p><p></p><p class="bulletIndent1">While the efficacy of <a class="drug drug_general" data-topicid="117669" href="/z/d/drug information/117669.html" rel="external">fostamatinib</a> was modest, many of the patients who had a response had previously tried many other treatments that were not effective, including splenectomy and thrombopoietin receptor agonists (TPO-RAs). In the FIT trials, patients had tried at least one prior therapy, and most had tried multiple (median, 3; range, up to 13) [<a href="#rid74">74</a>].</p><p></p><p class="headingAnchor" id="H2018877749"><span class="h2">Immunosuppressive agents</span><span class="headingEndMark"> — </span>Immunosuppressive agents other than glucocorticoids at the standard dose and schedule have been used to treat ITP, with case reports or small, uncontrolled series describing successful use [<a href="#rid19">19</a>]. However, these case series often included patients with mild short-term thrombocytopenia (ie, possibly not ITP) or had only a minority of patients with ITP unresponsive to splenectomy, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, or a TPO-RA [<a href="#rid77">77</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intermittent glucocorticoids</strong> – Although glucocorticoids are highly effective as initial therapy, we generally avoid long-term continuous and intermittent glucocorticoids due to toxicities with extended use and availability of other good options. An exception is the uncommon patient who is able to maintain a safe platelet count on very low-dose glucocorticoids (<a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> at a dose of ≤5 mg/day). (See  <a class="medical medical_review" href="/z/d/html/6677.html" rel="external">"Initial treatment of immune thrombocytopenia (ITP) in adults", section on 'Glucocorticoids and IVIG'</a>.)</p><p></p><p class="bulletIndent1">We sometimes use low-dose, intermittent glucocorticoids in patients who have a platelet count response. As an example, some patients maintain a safe platelet count on oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> at doses as low as 5 or 10 mg every other day. However, even these low doses can accelerate the development of osteoporosis and other glucocorticoid toxicities [<a href="#rid78">78-80</a>]. (See  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MMF</strong> – A study involving 46 individuals with severe ITP reported disease responses to <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (MMF) in 24 (52 percent); 15 had platelet counts over 100,000/microL [<a href="#rid81">81</a>]. The standard dose was 1 g daily. MMF has also been used in combination regimens. (See <a class="local">'Combinations'</a> below and  <a class="medical medical_review" href="/z/d/html/6677.html" rel="external">"Initial treatment of immune thrombocytopenia (ITP) in adults", section on 'Other therapies and multiagent combinations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Azathioprine</strong> – A series of 53 individuals with chronic ITP that persisted despite other therapies (splenectomy in 40) reported success with <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> at an initial oral dose of 150 mg/day; in some cases, several months of therapy was needed before a response was seen [<a href="#rid82">82</a>]. Thiopurine methyltransferase (TPMT) testing should be performed in all patients initiating azathioprine. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cyclosporine</strong><strong> </strong>– Therapies used by other clinicians in extreme circumstances with reports of success have included <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a>, and <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, alone or in combination, and hematopoietic stem cell transplant [<a href="#rid83">83-88</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> – We consider IVIG to be rescue treatment in ITP rather than routine, ongoing therapy. IVIG is important for patients with clinically important bleeding and for patients in whom a more rapid response is required [<a href="#rid19">19</a>]. (See  <a class="medical medical_review" href="/z/d/html/6677.html" rel="external">"Initial treatment of immune thrombocytopenia (ITP) in adults", section on 'IVIG dosing and administration'</a>.)</p><p></p><p class="headingAnchor" id="H1479115218"><span class="h2">Danazol and dapsone</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Danazol</strong> – <a class="drug drug_general" data-topicid="9321" href="/z/d/drug information/9321.html" rel="external">Danazol</a> is an attenuated androgen that may have efficacy in ITP. Danazol is generally well tolerated in males, but hirsutism can be a troubling side effect for females. In uncontrolled case series, platelet count responses to initial oral doses of 600 mg/day have been reported in up to 72 percent of patients [<a href="#rid89">89-91</a>]. Its efficacy in patients with chronic refractory ITP is unknown and may be limited [<a href="#rid19">19,92</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dapsone</strong><strong> </strong>– A series of 122 individuals treated in a referral center with <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a> reported responses in 81 (66 percent) [<a href="#rid93">93</a>]. The starting dose was 100 mg daily; higher doses did not improve the response rate. The cohort mostly consisted of individuals with chronic ITP, although some were treated with dapsone as their initial ITP therapy. Complete responses were seen in 29 (24 percent), with sustained responses in approximately one-half. Mild elevations in methemoglobin were common, with symptomatic methemoglobinemia in five individuals. (See  <a class="medical medical_review" href="/z/d/html/7094.html" rel="external">"Methemoglobinemia", section on 'Dapsone'</a>.)</p><p></p><p class="headingAnchor" id="H112549608"><span class="h2">Combinations</span><span class="headingEndMark"> — </span>In some patients who require therapy because of severe and symptomatic thrombocytopenia unresponsive to single agents, combinations of agents may be effective. The rationale for giving a combination of therapies include the need for more rapid effects of the faster-acting agents until the more durable effects of longer-acting agents take effect and the possibility of synergism between different agents [<a href="#rid94">94</a>]. </p><p>Combinations that have been tested include:</p><p class="bulletIndent1"><span class="glyph">●</span>Various combinations with a TPO-RA, especially with an agent that inhibits platelet clearance, such as <a class="drug drug_general" data-topicid="117669" href="/z/d/drug information/117669.html" rel="external">fostamatinib</a>, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, or a glucocorticoid. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Triple therapy given over 4 weeks (TT4) using high-dose oral <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (40 mg daily on days 1 to 4), oral <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> (2.5 to 3 mg/kg daily on days 1 to 28) and low-dose <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> (100 mg on days 7, 14, 21, and 28) [<a href="#rid95">95</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">Azathioprine</a>, MMF, and <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> [<a href="#rid96">96</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Glucocorticoids, <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a>, <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a>, and/or anti-D was administered to 35 patients whose disease did not respond to single-agent glucocorticoids, IVIG, or splenectomy, with or without <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> and <a class="drug drug_general" data-topicid="9321" href="/z/d/drug information/9321.html" rel="external">danazol</a> [<a href="#rid97">97</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Glucocorticoids, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, and <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="9815" href="/z/d/drug information/9815.html" rel="external">procarbazine</a>, or <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a> [<a href="#rid98">98</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9262" href="/z/d/drug information/9262.html" rel="external">All-trans retinoic acid</a> (ATRA) with low dose <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> [<a href="#rid99">99</a>].</p><p></p><p>For the most part, adverse events in these studies have been considered tolerable, but they are generally greater than seen in patients treated with single agents [<a href="#rid95">95-98,100,101</a>].</p><p class="headingAnchor" id="H881829377"><span class="h1">INVESTIGATIONAL THERAPIES</span></p><p class="headingAnchor" id="H4254364948"><span class="h2">Rilzabrutinib (investigational BTK inhibitor)</span><span class="headingEndMark"> — </span>Rilzabrutinib is an oral Bruton tyrosine kinase (BTK) inhibitor under investigation for several immune-mediated disorders.</p><p>In a 2022 open label dose-finding study, 60 patients with ITP and platelet count &lt;30,000/microL not responsive to other therapies were treated with one of several rilzabrutinib dosing regimens, with the option for dose escalation [<a href="#rid102">102</a>]. The median duration of ITP was six years, and patients had received a median of four prior therapies. Response, defined as platelet count &gt;50,000/microL and at least 20,000/microL over baseline on at least two occasions, occurred in 24 patients (40 percent). The median time to platelet count response was approximately 12 days. One-half of the participants had a treatment-related adverse event; all were mild (nausea, diarrhea, fatigue).</p><p>Increased specificity is thought to reduce the risk of off-target effects such as atrial fibrillation. Other BTK inhibitors can cause bleeding by inhibiting platelet aggregation, but rilzabrutinib does not appear to have this effect.</p><p class="headingAnchor" id="H1117178401"><span class="h2">Efgartigimod (investigational FcRn inhibitor)</span><span class="headingEndMark"> — </span>Efgartigimod reduces the levels of anti-platelet autoantibodies that may contribute to the pathophysiology of ITP; it does so by acting as a decoy for the neonatal Fc receptor (FcRn), in turn preventing FcRn from stabilizing circulating IgG [<a href="#rid103">103</a>].</p><p>In a 2023 randomized trial involving 131 adults with chronic or persistent ITP and platelet count &lt;30,000/microL, efgartigimod 10 mg/kg intravenously was more effective than placebo in raising the platelet count above 50,000/microL (22 versus 5 percent) [<a href="#rid104">104</a>]. The patients had longstanding ITP, with a mean of 10.6 years since diagnosis; two-thirds had received at least three prior ITP therapies, and slightly over one-third had a splenectomy. Therapy was well-tolerated, but regular intravenous infusions (once weekly or every other week) are required. </p><p class="headingAnchor" id="H1609151536"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/105473.html" rel="external">"Society guideline links: Immune thrombocytopenia (ITP) and other platelet disorders"</a>.)</p><p class="headingAnchor" id="H29"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Threshold for therapy</strong> – The goal of therapy is to provide a safe platelet count to prevent clinically important bleeding. We often initiate second-line therapy at a lower platelet count (&lt;20,000/microL) than first-line therapy (&lt;30,000/microL)  (<a class="graphic graphic_algorithm graphicRef130855" href="/z/d/graphic/130855.html" rel="external">algorithm 1</a>). Therapy is more important for patients with a higher risk of bleeding (comorbidities such as chronic kidney disease, concomitant antithrombotic agents, athletic activities). (See <a class="local">'Initial considerations'</a> above and  <a class="medical medical_review" href="/z/d/html/6677.html" rel="external">"Initial treatment of immune thrombocytopenia (ITP) in adults"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Before starting</strong> – Confirm the diagnosis, evaluate for treatable causes of secondary immune thrombocytopenia (ITP), and provide appropriate vaccinations prior to immunosuppressive therapy. (See <a class="local">'Initial considerations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choice of second-line therapy</strong> – The principle options are splenectomy, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, or a thrombopoietin receptor agonist (TPO-RA). These differ in mechanism of action, efficacy, administration, and adverse effects; the choice is individualized. We discuss risks and benefits of all options  (<a class="graphic graphic_table graphicRef95678" href="/z/d/graphic/95678.html" rel="external">table 1</a>) and assist the patient in arriving at a decision consistent with their values and preferences  (<a class="graphic graphic_algorithm graphicRef132516" href="/z/d/graphic/132516.html" rel="external">algorithm 2</a>). We avoid intravenous immunoglobulin (<a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a>), except in special circumstances, given its costs, complexity of administration, potential side effects, and transient effect.</p><p></p><p class="bulletIndent1">We are also trying to avoid immunosuppressive therapy when possible during the coronavirus disease 2019 (COVID-19) pandemic due to possible blunting of the immune response to COVID-19 vaccination. Receipt of immunosuppressive therapy has implications for COVID-19 vaccination. (See <a class="local">'COVID-19 vaccination'</a> above and  <a class="medical medical_review" href="/z/d/html/129849.html" rel="external">"COVID-19: Vaccines", section on 'Immunocompromised individuals'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Splenectomy</strong> – May be a good choice for an individual who wishes to have a potentially curative procedure (response rate, 80 to 90 percent) and avoid a regular medication, and who accepts risks of immunosuppression and venous thromboembolism (VTE). Predictors of efficacy include younger age and splenic sequestration on radiolabeled liver-spleen scan (not used routinely in the United States). The laparoscopic approach carries lower surgical morbidity and mortality. (See <a class="local">'Splenectomy'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>We often wait at least 12 months to allow time for late spontaneous remissions to occur.</p><p class="bulletIndent3"><span class="glyph">-</span>We provide preoperative immunizations. </p><p class="bulletIndent3"><span class="glyph">-</span>We suggest a laparoscopic rather than an open procedure (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Rituximab</strong> – May be a good choice for an individual who wishes to avoid surgery, prefers not to take a medication for an extended duration of time, and is willing to accept risks of immunosuppression and possible need for retreatment. Efficacy is 40 to 60 percent; median duration is approximately one year. Over the long-term follow-up, its efficacy is similar to placebo, and some individuals may require retreatment. (See <a class="local">'Rituximab'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>We provide immunizations and test hepatitis B virus (HBV) serologies prior to administration. </p><p class="bulletIndent3"><span class="glyph">-</span>The optimal dose is unknown; many clinicians use 375 mg/m<sup>2</sup> intravenously once a week for four consecutive weeks.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>TPO-RA</strong> – May be a good choice for an individual who wishes to avoid surgery and immunosuppression and is less concerned about the costs and burdens of taking a daily or weekly medication. Some individuals have a strong preference for the oral or subcutaneous route; of the oral agents, experience is greater with <a class="drug drug_general" data-topicid="9051" href="/z/d/drug information/9051.html" rel="external">eltrombopag</a> than <a class="drug drug_general" data-topicid="117929" href="/z/d/drug information/117929.html" rel="external">avatrombopag</a>. Adverse effects include VTE and bone marrow fibrosis (reversible and generally not clinically significant). Close platelet count monitoring is used to avoid thrombocytosis. Eltrombopag requires liver enzyme testing. These agents are expensive. (See <a class="local">'TPO receptor agonists'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Romiplostim</strong> – Weekly subcutaneous injection.</p><p class="bulletIndent3"><span class="glyph">-</span><strong>Eltrombopag</strong> – Oral daily pill taken without polyvalent cations.</p><p class="bulletIndent3"><span class="glyph">-</span><strong>Avatrombopag</strong><strong> </strong>– Oral daily pill taken with food.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Third-line therapies</strong> – Options include <a class="drug drug_general" data-topicid="117669" href="/z/d/drug information/117669.html" rel="external">fostamatinib</a>, immunosuppressive agents, <a class="drug drug_general" data-topicid="9321" href="/z/d/drug information/9321.html" rel="external">danazol</a>, <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a>, and combinations. Choices are individualized; it may take time to find the best approach for each patient. (See <a class="local">'Other therapies'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children and pregnancy</strong> – (See  <a class="medical medical_review" href="/z/d/html/5917.html" rel="external">"Immune thrombocytopenia (ITP) in children: Initial management"</a> and  <a class="medical medical_review" href="/z/d/html/89225.html" rel="external">"Immune thrombocytopenia (ITP) in children: Management of chronic disease"</a> and  <a class="medical medical_review" href="/z/d/html/6681.html" rel="external">"Thrombocytopenia in pregnancy", section on 'Immune thrombocytopenia (ITP)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis and initial therapy</strong> – (See  <a class="medical medical_review" href="/z/d/html/6676.html" rel="external">"Immune thrombocytopenia (ITP) in adults: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/6677.html" rel="external">"Initial treatment of immune thrombocytopenia (ITP) in adults"</a>.)</p><p></p><p class="headingAnchor" id="H1746998582"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges James N George, MD, who contributed to many earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 2019; 3:3829.</a></li><li><a class="nounderline abstract_t">Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv 2019; 3:3780.</a></li><li><a class="nounderline abstract_t">Arnold DM, Nazy I, Clare R, et al. Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP Registry. Blood Adv 2017; 1:2414.</a></li><li><a class="nounderline abstract_t">Cuker A. Transitioning patients with immune thrombocytopenia to second-line therapy: Challenges and best practices. Am J Hematol 2018; 93:816.</a></li><li><a class="nounderline abstract_t">Arnold DM, Heddle NM, Cook RJ, et al. Perioperative oral eltrombopag versus intravenous immunoglobulin in patients with immune thrombocytopenia: a non-inferiority, multicentre, randomised trial. Lancet Haematol 2020; 7:e640.</a></li><li><a class="nounderline abstract_t">Bylsma LC, Fryzek JP, Cetin K, et al. Systematic literature review of treatments used for adult immune thrombocytopenia in the second-line setting. Am J Hematol 2019; 94:118.</a></li><li><a class="nounderline abstract_t">Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004; 104:2623.</a></li><li><a class="nounderline abstract_t">Patel VL, Mahévas M, Lee SY, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood 2012; 119:5989.</a></li><li><a class="nounderline abstract_t">Arnold DM, Dentali F, Crowther MA, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007; 146:25.</a></li><li><a class="nounderline abstract_t">Aleem A, Alaskar AS, Algahtani F, et al. Rituximab in immune thrombocytopenia: transient responses, low rate of sustained remissions and poor response to further therapy in refractory patients. Int J Hematol 2010; 92:283.</a></li><li><a class="nounderline abstract_t">Ghanima W, Khelif A, Waage A, et al. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2015; 385:1653.</a></li><li><a class="nounderline abstract_t">Arnold DM. Positioning new treatments in the management of immune thrombocytopenia. Pediatr Blood Cancer 2013; 60 Suppl 1:S19.</a></li><li><a class="nounderline abstract_t">Lal LS, Said Q, Andrade K, Cuker A. Second-line treatments and outcomes for immune thrombocytopenia: A retrospective study with electronic health records. Res Pract Thromb Haemost 2020; 4:1131.</a></li><li><a class="nounderline abstract_t">Rodeghiero F, Ruggeri M. Is splenectomy still the gold standard for the treatment of chronic ITP? Am J Hematol 2008; 83:91.</a></li><li><a class="nounderline abstract_t">Cooper N, Evangelista ML, Amadori S, Stasi R. Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura? Curr Opin Hematol 2007; 14:642.</a></li><li class="breakAll">https://www.ashclinicalnews.org/on-location/ash-annual-meeting/romiplostim-eltrombopag-beat-rituximab-secondline-chronic-immune-thrombocytopenia-treatment/ (Accessed on July 30, 2021).</li><li><a class="nounderline abstract_t">Rodeghiero F. A critical appraisal of the evidence for the role of splenectomy in adults and children with ITP. Br J Haematol 2018; 181:183.</a></li><li><a class="nounderline abstract_t">George JN. Management of immune thrombocytopenia--something old, something new. N Engl J Med 2010; 363:1959.</a></li><li><a class="nounderline abstract_t">George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996; 88:3.</a></li><li><a class="nounderline abstract_t">Gonzalez-Porras JR, Escalante F, Pardal E, et al. Safety and efficacy of splenectomy in over 65-yrs-old patients with immune thrombocytopenia. Eur J Haematol 2013; 91:236.</a></li><li><a class="nounderline abstract_t">Fenaux P, Caulier MT, Hirschauer MC, et al. Reevaluation of the prognostic factors for splenectomy in chronic idiopathic thrombocytopenic purpura (ITP): a report on 181 cases. Eur J Haematol 1989; 42:259.</a></li><li><a class="nounderline abstract_t">Fabris F, Tassan T, Ramon R, et al. Age as the major predictive factor of long-term response to splenectomy in immune thrombocytopenic purpura. Br J Haematol 2001; 112:637.</a></li><li><a class="nounderline abstract_t">Law C, Marcaccio M, Tam P, et al. High-dose intravenous immune globulin and the response to splenectomy in patients with idiopathic thrombocytopenic purpura. N Engl J Med 1997; 336:1494.</a></li><li><a class="nounderline abstract_t">Amini SN, Nelson VS, Sobels A, et al. Autologous platelet scintigraphy and clinical outcome of splenectomy in immune thrombocytopenia: A systematic review and meta-analysis. Crit Rev Oncol Hematol 2020; 153:103040.</a></li><li><a class="nounderline abstract_t">Wu JM, Lai IR, Yuan RH, Yu SC. Laparoscopic splenectomy for idiopathic thrombocytopenic purpura. Am J Surg 2004; 187:720.</a></li><li><a class="nounderline abstract_t">Keidar A, Feldman M, Szold A. Analysis of outcome of laparoscopic splenectomy for idiopathic thrombocytopenic purpura by platelet count. Am J Hematol 2005; 80:95.</a></li><li><a class="nounderline abstract_t">Thomsen RW, Schoonen WM, Farkas DK, et al. Risk for hospital contact with infection in patients with splenectomy: a population-based cohort study. Ann Intern Med 2009; 151:546.</a></li><li><a class="nounderline abstract_t">Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005; 8:140.</a></li><li><a class="nounderline abstract_t">Chugh S, Darvish-Kazem S, Lim W, et al. Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis. Lancet Haematol 2015; 2:e75.</a></li><li><a class="nounderline abstract_t">Auger S, Duny Y, Rossi JF, Quittet P. Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysis. Br J Haematol 2012; 158:386.</a></li><li><a class="nounderline abstract_t">Nazi I, Kelton JG, Larché M, et al. The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood 2013; 122:1946.</a></li><li><a class="nounderline abstract_t">Zaja F, Vianelli N, Volpetti S, et al. Low-dose rituximab in adult patients with primary immune thrombocytopenia. Eur J Haematol 2010; 85:329.</a></li><li><a class="nounderline abstract_t">Zaja F, Volpetti S, Chiozzotto M, et al. Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia. Am J Hematol 2012; 87:886.</a></li><li><a class="nounderline abstract_t">Tran H, Brighton T, Grigg A, et al. A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study). Br J Haematol 2014; 167:243.</a></li><li><a class="nounderline abstract_t">Khellaf M, Charles-Nelson A, Fain O, et al. Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. Blood 2014; 124:3228.</a></li><li><a class="nounderline abstract_t">Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113:4834.</a></li><li><a class="nounderline abstract_t">George JN, Terrell DR. Novel thrombopoietic agents: a new era for management of patients with thrombocytopenia. Haematologica 2008; 93:1445.</a></li><li><a class="nounderline abstract_t">Zeng Y, Duan X, Xu J, Ni X. TPO receptor agonist for chronic idiopathic thrombocytopenic purpura. Cochrane Database Syst Rev 2011; :CD008235.</a></li><li><a class="nounderline abstract_t">González-López TJ, Pascual C, Álvarez-Román MT, et al. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia. Am J Hematol 2015; 90:E40.</a></li><li><a class="nounderline abstract_t">Ghadaki B, Nazi I, Kelton JG, Arnold DM. Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists. Transfusion 2013; 53:2807.</a></li><li><a class="nounderline abstract_t">Broudy VC, Lin NL. AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine 2004; 25:52.</a></li><li><a class="nounderline abstract_t">Newland A, Caulier MT, Kappers-Klunne M, et al. An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol 2006; 135:547.</a></li><li><a class="nounderline abstract_t">Molineux G, Newland A. Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside. Br J Haematol 2010; 150:9.</a></li><li><a class="nounderline abstract_t">Wang S, Yang R, Zou P, et al. A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia. Int J Hematol 2012; 96:222.</a></li><li><a class="nounderline abstract_t">Kong Z, Qin P, Xiao S, et al. A novel recombinant human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy. Blood 2017; 130:1097.</a></li><li><a class="nounderline abstract_t">Kuter DJ, Bussel JB, Newland A, et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol 2013; 161:411.</a></li><li><a class="nounderline abstract_t">Kuter DJ, Rummel M, Boccia R, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 2010; 363:1889.</a></li><li><a class="nounderline abstract_t">Tomiyama Y, Miyakawa Y, Okamoto S, et al. A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia. J Thromb Haemost 2012; 10:799.</a></li><li><a class="nounderline abstract_t">Kuter DJ. The biology of thrombopoietin and thrombopoietin receptor agonists. Int J Hematol 2013; 98:10.</a></li><li><a class="nounderline abstract_t">Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 2006; 355:1672.</a></li><li><a class="nounderline abstract_t">Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008; 371:395.</a></li><li><a class="nounderline abstract_t">Khellaf M, Michel M, Quittet P, et al. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program. Blood 2011; 118:4338.</a></li><li><a class="nounderline abstract_t">Shirasugi Y, Ando K, Miyazaki K, et al. Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial. Int J Hematol 2011; 94:71.</a></li><li><a class="nounderline abstract_t">Cines DB, Gernsheimer T, Wasser J, et al. Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim. Int J Hematol 2015; 102:259.</a></li><li><a class="nounderline abstract_t">Bussel JB, Kuter DJ, Pullarkat V, et al. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009; 113:2161.</a></li><li><a class="nounderline abstract_t">George JN, Mathias SD, Go RS, et al. Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials. Br J Haematol 2009; 144:409.</a></li><li><a class="nounderline abstract_t">Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373:641.</a></li><li><a class="nounderline abstract_t">Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011; 377:393.</a></li><li><a class="nounderline abstract_t">Saleh MN, Bussel JB, Cheng G, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood 2013; 121:537.</a></li><li><a class="nounderline abstract_t">Wong RSM, Saleh MN, Khelif A, et al. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood 2017; 130:2527.</a></li><li><a class="nounderline abstract_t">Cheng G. Thrombopoietin Receptor Agonists for the treatment of ITP. Rinsho Ketsueki 2013; 54:1915.</a></li><li><a class="nounderline abstract_t">Ghanima W, Geyer JT, Lee CS, et al. Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up. Haematologica 2014; 99:937.</a></li><li><a class="nounderline abstract_t">Bussel JB, Kuter DJ, Aledort LM, et al. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood 2014; 123:3887.</a></li><li><a class="nounderline abstract_t">Jurczak W, Chojnowski K, Mayer J, et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. Br J Haematol 2018; 183:479.</a></li><li><a class="nounderline abstract_t">Bussel JB. Avatrombopag. Br J Haematol 2018; 183:342.</a></li><li><a class="nounderline abstract_t">Catalá-López F, Corrales I, de la Fuente-Honrubia C, et al. Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: Systematic review and meta-analysis of randomized controlled trials. Med Clin (Barc) 2015; 145:511.</a></li><li><a class="nounderline abstract_t">Kuter DJ, Allen LF. Avatrombopag, an oral thrombopoietin receptor agonist: results of two double-blind, dose-rising, placebo-controlled Phase 1 studies. Br J Haematol 2018; 183:466.</a></li><li><a class="nounderline abstract_t">Janssens A, Rodeghiero F, Anderson D, et al. Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia. Ann Hematol 2016; 95:1077.</a></li><li><a class="nounderline abstract_t">Brynes RK, Orazi A, Theodore D, et al. Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: Data from the EXTEND study. Am J Hematol 2015; 90:598.</a></li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209299lbl.pdf (Accessed on May 21, 2018).</li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209299lbl.pdf (Accessed on April 24, 2018).</li><li><a class="nounderline abstract_t">Newland A, Lee EJ, McDonald V, Bussel JB. Fostamatinib for persistent/chronic adult immune thrombocytopenia. Immunotherapy 2018; 10:9.</a></li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209299lbl.pdf (Accessed on January 26, 2022).</li><li><a class="nounderline abstract_t">Bussel J, Arnold DM, Grossbard E, et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials. Am J Hematol 2018; 93:921.</a></li><li><a class="nounderline abstract_t">Bussel JB, Arnold DM, Boxer MA, et al. Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program. Am J Hematol 2019; 94:546.</a></li><li><a class="nounderline abstract_t">Podolanczuk A, Lazarus AH, Crow AR, et al. Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood 2009; 113:3154.</a></li><li><a class="nounderline abstract_t">Vesely SK, Perdue JJ, Rizvi MA, et al. Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy: a systematic review. Ann Intern Med 2004; 140:112.</a></li><li><a class="nounderline abstract_t">van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002; 13:777.</a></li><li><a class="nounderline abstract_t">Guidry JA, George JN, Vesely SK, et al. Corticosteroid side-effects and risk for bleeding in immune thrombocytopenic purpura: patient and hematologist perspectives. Eur J Haematol 2009; 83:175.</a></li><li class="breakAll">Zukerman E, Ingelfinger JR. Coping with Prednisone, St Martin's Press, New York 2007.</li><li><a class="nounderline abstract_t">Taylor A, Neave L, Solanki S, et al. Mycophenolate mofetil therapy for severe immune thrombocytopenia. Br J Haematol 2015; 171:625.</a></li><li><a class="nounderline abstract_t">Quiquandon I, Fenaux P, Caulier MT, et al. Re-evaluation of the role of azathioprine in the treatment of adult chronic idiopathic thrombocytopenic purpura: a report on 53 cases. Br J Haematol 1990; 74:223.</a></li><li><a class="nounderline abstract_t">Verlin M, Laros RK Jr, Penner JA. Treatment of refractory thrombocytopenic purpura with cyclophosphamine. Am J Hematol 1976; 1:97.</a></li><li><a class="nounderline abstract_t">Reiner A, Gernsheimer T, Slichter SJ. Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura. Blood 1995; 85:351.</a></li><li><a class="nounderline abstract_t">Zaja F, Marin L, Chiozzotto M, et al. Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab. Am J Hematol 2012; 87:321.</a></li><li><a class="nounderline abstract_t">Rodrigo C, Gooneratne L. Dapsone for primary immune thrombocytopenia in adults and children: an evidence-based review. J Thromb Haemost 2013; 11:1946.</a></li><li><a class="nounderline abstract_t">Huhn RD, Fogarty PF, Nakamura R, et al. High-dose cyclophosphamide with autologous lymphocyte-depleted peripheral blood stem cell (PBSC) support for treatment of refractory chronic autoimmune thrombocytopenia. Blood 2003; 101:71.</a></li><li><a class="nounderline abstract_t">Passweg JR, Rabusin M, Musso M, et al. Haematopoetic stem cell transplantation for refractory autoimmune cytopenia. Br J Haematol 2004; 125:749.</a></li><li><a class="nounderline abstract_t">Ahn YS, Rocha R, Mylvaganam R, et al. Long-term danazol therapy in autoimmune thrombocytopenia: unmaintained remission and age-dependent response in women. Ann Intern Med 1989; 111:723.</a></li><li><a class="nounderline abstract_t">Maloisel F, Andrès E, Zimmer J, et al. Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: long-term results. Am J Med 2004; 116:590.</a></li><li><a class="nounderline abstract_t">Andrès E, Zimmer J, Noel E, et al. Idiopathic thrombocytopenic purpura: a retrospective analysis in 139 patients of the influence of age on the response to corticosteroids, splenectomy and danazol. Drugs Aging 2003; 20:841.</a></li><li><a class="nounderline abstract_t">Stasi R, Provan D. Management of immune thrombocytopenic purpura in adults. Mayo Clin Proc 2004; 79:504.</a></li><li><a class="nounderline abstract_t">Colella MP, Orsi FA, Alves ECF, et al. A retrospective analysis of 122 immune thrombocytopenia patients treated with dapsone: Efficacy, safety and factors associated with treatment response. J Thromb Haemost 2021; 19:2275.</a></li><li><a class="nounderline abstract_t">Zhou H, Xu M, Qin P, et al. A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP. Blood 2015; 125:1541.</a></li><li><a class="nounderline abstract_t">Choi PY, Roncolato F, Badoux X, et al. A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4). Blood 2015; 126:500.</a></li><li><a class="nounderline abstract_t">Arnold DM, Nazi I, Santos A, et al. Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura. Blood 2010; 115:29.</a></li><li><a class="nounderline abstract_t">Boruchov DM, Gururangan S, Driscoll MC, Bussel JB. Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP). Blood 2007; 110:3526.</a></li><li><a class="nounderline abstract_t">Figueroa M, Gehlsen J, Hammond D, et al. Combination chemotherapy in refractory immune thrombocytopenic purpura. N Engl J Med 1993; 328:1226.</a></li><li><a class="nounderline abstract_t">Wu YJ, Liu H, Zeng QZ, et al. All-trans retinoic acid plus low-dose rituximab vs low-dose rituximab in corticosteroid-resistant or relapsed ITP. Blood 2022; 139:333.</a></li><li><a class="nounderline abstract_t">Gudbrandsdottir S, Birgens HS, Frederiksen H, et al. Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. Blood 2013; 121:1976.</a></li><li><a class="nounderline abstract_t">Zaja F, Baccarani M, Mazza P, et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood 2010; 115:2755.</a></li><li><a class="nounderline abstract_t">Kuter DJ, Efraim M, Mayer J, et al. Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia. N Engl J Med 2022; 386:1421.</a></li><li><a class="nounderline abstract_t">Mahamad S, Arnold DM. Inhibition of neonatal Fc receptor as a treatment for immune thrombocytopenia. Lancet 2023; 402:1599.</a></li><li><a class="nounderline abstract_t">Broome CM, McDonald V, Miyakawa Y, et al. Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2023; 402:1648.</a></li></ol></div><div id="topicVersionRevision">Topic 6678 Version 66.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31794604" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : American Society of Hematology 2019 guidelines for immune thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31770441" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Updated international consensus report on the investigation and management of primary immune thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29296891" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29574922" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Transitioning patients with immune thrombocytopenia to second-line therapy: Challenges and best practices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32853584" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Perioperative oral eltrombopag versus intravenous immunoglobulin in patients with immune thrombocytopenia: a non-inferiority, multicentre, randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30264861" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Systematic literature review of treatments used for adult immune thrombocytopenia in the second-line setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15217831" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22566601" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17200219" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20640541" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Rituximab in immune thrombocytopenia: transient responses, low rate of sustained remissions and poor response to further therapy in refractory patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25662413" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23109488" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Positioning new treatments in the management of immune thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33134779" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Second-line treatments and outcomes for immune thrombocytopenia: A retrospective study with electronic health records.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17994550" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Is splenectomy still the gold standard for the treatment of chronic ITP?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17898569" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17898569" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29479668" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A critical appraisal of the evidence for the role of splenectomy in adults and children with ITP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21067388" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Management of immune thrombocytopenia--something old, something new.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8704187" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23679653" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Safety and efficacy of splenectomy in over 65-yrs-old patients with immune thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2924888" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Reevaluation of the prognostic factors for splenectomy in chronic idiopathic thrombocytopenic purpura (ITP): a report on 181 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11260065" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Age as the major predictive factor of long-term response to splenectomy in immune thrombocytopenic purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9154768" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : High-dose intravenous immune globulin and the response to splenectomy in patients with idiopathic thrombocytopenic purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32712518" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Autologous platelet scintigraphy and clinical outcome of splenectomy in immune thrombocytopenia: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15191864" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Laparoscopic splenectomy for idiopathic thrombocytopenic purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16184593" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Analysis of outcome of laparoscopic splenectomy for idiopathic thrombocytopenic purpura by platelet count.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19841456" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Risk for hospital contact with infection in patients with splenectomy: a population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15564720" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The biology of CD20 and its potential as a target for mAb therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26687612" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22612239" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23851398" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The effect of rituximab on vaccine responses in patients with immune thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20546023" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Low-dose rituximab in adult patients with primary immune thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22718483" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25041261" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25293768" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19264918" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18827261" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Novel thrombopoietic agents: a new era for management of patients with thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21735426" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : TPO receptor agonist for chronic idiopathic thrombocytopenic purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25400215" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23451917" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14693160" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17061981" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20298251" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22753022" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28630121" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : A novel recombinant human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23432528" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21067381" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Romiplostim or standard of care in patients with immune thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22409309" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23821332" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The biology of thrombopoietin and thrombopoietin receptor agonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17050891" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18242413" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21832276" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21706145" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26201709" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18981291" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19016720" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19231632" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20739054" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23169778" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29042367" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24064843" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Thrombopoietin Receptor Agonists for the treatment of ITP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24463212" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24802775" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30191972" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30351482" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Avatrombopag.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26051432" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: Systematic review and meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30203841" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Avatrombopag, an oral thrombopoietin receptor agonist: results of two double-blind, dose-rising, placebo-controlled Phase 1 studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27130310" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25801698" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: Data from the EXTEND study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25801698" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: Data from the EXTEND study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25801698" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: Data from the EXTEND study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28967793" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Fostamatinib for persistent/chronic adult immune thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28967793" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Fostamatinib for persistent/chronic adult immune thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29696684" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30784097" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19096013" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14734334" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12378366" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19374704" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Corticosteroid side-effects and risk for bleeding in immune thrombocytopenic purpura: patient and hematologist perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19374704" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Corticosteroid side-effects and risk for bleeding in immune thrombocytopenic purpura: patient and hematologist perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26250874" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Mycophenolate mofetil therapy for severe immune thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2317458" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Re-evaluation of the role of azathioprine in the treatment of adult chronic idiopathic thrombocytopenic purpura: a report on 53 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/988746" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Treatment of refractory thrombocytopenic purpura with cyclophosphamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7811992" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22190262" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23927583" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Dapsone for primary immune thrombocytopenia in adults and children: an evidence-based review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12393623" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : High-dose cyclophosphamide with autologous lymphocyte-depleted peripheral blood stem cell (PBSC) support for treatment of refractory chronic autoimmune thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15180864" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Haematopoetic stem cell transplantation for refractory autoimmune cytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2802430" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Long-term danazol therapy in autoimmune thrombocytopenia: unmaintained remission and age-dependent response in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15093754" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: long-term results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12964890" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Idiopathic thrombocytopenic purpura: a retrospective analysis in 139 patients of the influence of age on the response to corticosteroids, splenectomy and danazol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15065616" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Management of immune thrombocytopenic purpura in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34018665" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : A retrospective analysis of 122 immune thrombocytopenia patients treated with dapsone: Efficacy, safety and factors associated with treatment response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25575541" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25972158" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19897578" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17698634" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8464433" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Combination chemotherapy in refractory immune thrombocytopenic purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34665865" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : All-trans retinoic acid plus low-dose rituximab vs low-dose rituximab in corticosteroid-resistant or relapsed ITP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23293082" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20130241" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35417637" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37778357" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Inhibition of neonatal Fc receptor as a treatment for immune thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37778358" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
